AIG
JANX icon

American International Group’s Janux Therapeutics JANX Stock Holding History

American International Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,524
Closed -$321K – 1359
2024
Q1 		$321K Sell
8,524
-72
-0.8% -$1.57K ﹤0.01% 1877
2023
Q4 		$92.2K Sell
8,596
-35
-0.4% -$303 ﹤0.01% 2607
2023
Q3 		$87K Buy
8,631
+307
+4% +$3.54K ﹤0.01% 2579
2023
Q2 		$98.8K Buy
8,324
+42
+0.5% +$561 ﹤0.01% 2581
2023
Q1 		$100K Buy
8,282
+164
+2% +$2.73K ﹤0.01% 2451
2022
Q4 		$107K Sell
8,118
-29
-0.4% -$424 ﹤0.01% 2472
2022
Q3 		$110K Buy
8,147
+115
+1% +$1.54K ﹤0.01% 2496
2022
Q2 		$98K Sell
8,032
-781
-9% -$9.25K ﹤0.01% 2610
2022
Q1 		$126K Buy
8,813
+1,782
+25% +$29.2K ﹤0.01% 2493
2021
Q4 		$139K Sell
7,031
-211
-3% -$4.42K ﹤0.01% 2568
2021
Q3 		$157K Buy
+7,242
New +$208K ﹤0.01% 2576

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

American International Group's JANX Position: Q2 2024 in Review

American International Group sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 8,524 shares — an estimated $321K sold.

American International Group first reported a position in JANX in Q3 2021 and held it in 11 quarters. The position peaked at $321K in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

  • American International Group reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 8,524 Janux Therapeutics shares in Q2 2024, an estimated $321K.
  • American International Group first reported a position in Janux Therapeutics in Q3 2021 and held it in 11 quarters.
  • American International Group's Janux Therapeutics position peaked at $321K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.